GlassScriptPhysician profile
Rachel Weeks
NPI 1033805585
$3,901.38
in general payments reported to CMS, 2019-2025
31 companies · $1,791 in 2025
The $1,791 reported for 2025 was more than what 94% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $614 · 2024: $1,497 · 2025: $1,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,875 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,875.43 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $461.49 | 2024-2025 | Talvey, Erleada, Darzalex |
| Astrazeneca Pharmaceuticals LP | $384.85 | 2023-2025 | Enhertu, Calquence, Imfinzi |
| Daiichi Sankyo INC. | $382.25 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| Eisai INC. | $353.49 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $269.83 | 2023-2025 | |
| Incyte Corporation | $201.04 | 2023-2025 | Monjuvi, Pemazyre, Jakafi |
| Genmab U.S., INC. | $169.36 | 2023-2025 | Tivdak |
| Bayer Healthcare Pharmaceuticals INC. | $161.89 | 2023-2025 | |
| Genzyme Corporation | $161.21 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.02 | 2023-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Gilead Sciences, INC. | $128.71 | 2024 | Trodelvy |
| Merck Sharp & Dohme LLC | $114.64 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genentech USA, INC. | $112.36 | 2023-2025 | Polivy, Columvi, Lunsumio |
| Regeneron Healthcare Solutions, INC. | $84.23 | 2023-2025 | Libtayo |
| Celgene Corporation | $70.99 | 2023-2025 | Reblozyl, Pomalyst |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $68.14 | 2025 | Monoferric |
| E.R. Squibb & Sons, L.L.C. | $67.10 | 2024-2025 | Opdualag, Krazati |
| Stemline Therapeutics INC. | $66.23 | 2024-2025 | Orserdu |
| Abbvie INC. | $65.42 | 2024 | |
| Exelixis INC. | $64.86 | 2023-2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $50.48 | 2023-2024 | Ultomiris |
| Caris Mpi, INC. | $46.36 | 2025 | Mi Cancer Seek |
| Adc Therapeutics America, INC. | $44.00 | 2024 | |
| Sobi, INC | $43.86 | 2025 | |
| Jazz Pharmaceuticals INC. | $38.95 | 2024-2025 | |
| Mirati Therapeutics, INC. | $37.83 | 2023 | Krazati |
| Sumitomo Pharma America, INC. | $29.04 | 2025 | Orgovyx |
| Novocure INC. | $21.46 | 2025 | Optune Lua (Novottf-200t) |
| Pfizer INC. | $18.63 | 2025 | |
| Deciphera Pharmaceuticals INC. | $15.28 | 2023 | Qinlock |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.38 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Weeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.